BRIEF published on 11/24/2025 at 06:35, 2 months 9 days ago Formycon Partners with NTC for Biosimilar Commercialization in Italy Formycon AG Ophthalmology Biosimilar Partnerships Italy Pharmaceutical Market FYB203/Baiama®
PRESS RELEASE published on 11/24/2025 at 06:30, 2 months 9 days ago NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy Formycon AG partners with NTC for Eylea biosimilar commercialization in Italy. Agreement includes royalties and supply chain organization Italy Formycon AG Commercialization Eylea Biosimilar NTC
BRIEF published on 11/20/2025 at 17:05, 2 months 13 days ago First Berlin réaffirme sa recommandation d'achat sur Formycon AG Formycon AG Dupixent Évaluation D'achat Prévisions De Recettes Biosimilaire De Keytruda
BRIEF published on 11/20/2025 at 17:05, 2 months 13 days ago First Berlin Reaffirms Buy Rating for Formycon AG BUY Rating Formycon AG Revenue Guidance Dupixent Keytruda Biosimilar
PRESS RELEASE published on 11/20/2025 at 17:00, 2 months 13 days ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Buy recommendation on Formycon AG (DE000A1EWVY8) to EUR 53 target price post Q3 results surpassing expectations and upcoming FYB206 study endpoint results First Berlin Equity Research Buy Recommendation Formycon AG FYB206 EUR 53 Target Price
BRIEF published on 11/20/2025 at 06:35, 2 months 13 days ago Lancement en Allemagne du biosimilaire de ranibizumab Epruvy® Formycon AG Ranibizumab Biosimilaire Lancement En Allemagne Soins Ophtalmiques
BRIEF published on 11/20/2025 at 06:35, 2 months 13 days ago Ranibizumab Biosimilar Epruvy® Launched in Germany Formycon AG Ranibizumab Biosimilar Germany Launch Ophthalmic Care
PRESS RELEASE published on 11/20/2025 at 06:30, 2 months 13 days ago Ranibizumab Biosimilar Epruvy® launched in Germany Ranibizumab Biosimilar Epruvy® launched in Germany by Formycon AG, Bioeq AG, and Sandoz AG under license agreement, expanding patient access to treatment options for nAMD and retinopathies Formycon AG Germany Ranibizumab Sandoz AG Epruvy
BRIEF published on 11/17/2025 at 06:35, 2 months 16 days ago Formycon Reaches Milestone with FYB208 for Dupixent® Biosimilars Formycon Chronic Inflammatory Diseases Dupilumab Technical Proof Of Similarity
BRIEF published on 11/17/2025 at 06:35, 2 months 16 days ago Formycon franchit une étape importante avec FYB208 pour Dupixent® Maladies Inflammatoires Chroniques Formycon Biosimilaires Dupilumab Preuve Technique De Similitude
Published on 02/03/2026 at 22:15, 8 minutes ago Amdocs Introduces aOS: An Agentic Operating System for Telecommunications
Published on 02/03/2026 at 22:15, 8 minutes ago FP Canadian Newspapers LP Announces Appointment of CAO
Published on 02/03/2026 at 22:15, 8 minutes ago Roxmore Resources Announces Uplisting To Toronto Stock Exchange
Published on 02/03/2026 at 22:15, 8 minutes ago Meta Critical Minerals Announces Private Placement With Strategic Advisory Support From Leading New York Investment Bank Revere Securities
Published on 02/03/2026 at 22:15, 8 minutes ago Prince Silver Increases Private Placement to up to $4.75 Million
Published on 02/03/2026 at 20:57, 1 hour 26 minutes ago EQS-Adhoc: tick Trading Software AG adjusts forecast for the current 2025/2026 fiscal year
Published on 02/03/2026 at 20:36, 1 hour 46 minutes ago Freelance.com: Agenda de communication financière 2026-2027
Published on 02/03/2026 at 20:05, 2 hours 18 minutes ago KHUFU'S IN EGYPT NAMED NO.1 AT MIDDLE EAST & NORTH AFRICA'S 50 BEST RESTAURANTS 2026
Published on 02/03/2026 at 19:50, 2 hours 33 minutes ago Blockchain.com & Ondo Finance Launch Onchain Tokenized U.S. Stocks Across Europe
Published on 02/03/2026 at 18:00, 4 hours 23 minutes ago Mint dépasse ses ambitions annoncées pour 2025 grâce à des succès commerciaux majeurs dans le BtoB
Published on 02/03/2026 at 17:45, 4 hours 38 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 02/03/2026 at 17:45, 4 hours 38 minutes ago Chiffre d’affaires 2025 en croissance à 11,2 M€ (+5%)
